Haematologica, Vol 92, Issue 10, 1411-1414 doi:10.3324/haematol.11463
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ludwig, H.
Right arrow Articles by Meran, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ludwig, H.
Right arrow Articles by Meran, J. G.
Related Collections
Right arrowRelated Article

Multiple Myeloma

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

Heinz Ludwig, Johannes Drach, Helmut Graf, Alois Lang, Johannes Gobertus Meran

From the Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria (HL); Department of Internal Medicine I, Division of Oncology, University Hospital, Vienna, Austria (JD); Internal Department III, Krankenanstalt Rudolfstiftung, Vienna, Austria (HG); Department of Internal Medicine, LKH Feldkirch, Feldkirch, Austria (AL); Department of Internal Medicine, Krankenhaus der Barmherzigen Brueder, Vienna, Austria (JM)

Correspondence: Heinz Ludwig, Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1170 Vienna, Austria. E-mail: heinz.ludwig{at}wienkav.at

Paraprotein induced renal failure is a frequent complication of multiple myeloma and is associated with poor survival. Previously, reversal of renal function has been hampered by the lack of fast acting and highly effective myeloma therapy and most patients remained or became dependent on hemodialysis. Here we show reversal of acute paraprotein-induced renal failure by bortezomib-based therapy in 5 out of 8 patients. Improvement of renal function was preceded by a significant reduction in paraprotein concentration in all patients, with improvement in renal function.

Key words: acute paraprotein-induced renal failure, multiple myeloma, nephrotoxic light chains, bortezomib, hemodialysis.


Related Article

Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Roberto Sitia, Giovanni Palladini, Giampaolo Merlini
Haematologica 2007 92: 1302-1307. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 The OncologistHome page
H. Ludwig, M. Beksac, J. Blade, M. Boccadoro, J. Cavenagh, M. Cavo, M. Dimopoulos, J. Drach, H. Einsele, T. Facon, et al.
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Oncologist, January 1, 2010; 15(1): 6 - 25.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, P. G. Richardson, R. Schlag, N. K. Khuageva, O. Shpilberg, E. Kastritis, M. Kropff, M. T. Petrucci, M. Delforge, J. Alexeeva, et al.
VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
J. Clin. Oncol., December 20, 2009; 27(36): 6086 - 6093.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
C. A. Hutchison, A. R. Bradwell, M. Cook, K. Basnayake, S. Basu, S. Harding, J. Hattersley, N. D. Evans, M. J. Chappel, P. Sampson, et al.
Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis
Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 745 - 754.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Terpos, E. Katodritou, E. Tsiftsakis, E. Kastritis, D. Christoulas, A. Pouli, E. Michalis, E. Verrou, K. Anargyrou, K. Tsionos, et al.
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Haematologica, March 1, 2009; 94(3): 372 - 379.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Kastritis, M. Migkou, M. Gavriatopoulou, P. Zirogiannis, V. Hadjikonstantinou, and M. A. Dimopoulos
Treatment of light chain deposition disease with bortezomib and dexamethasone
Haematologica, February 1, 2009; 94(2): 300 - 302.
[Full Text] [PDF]

Home page
 haematolHome page
R. Sitia, G. Palladini, and G. Merlini
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Haematologica, October 1, 2007; 92(10): 1302 - 1307.
[Full Text] [PDF]